GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (CHIX:ARGXb) » Definitions » Cyclically Adjusted Revenue per Share

argenx SE (CHIX:ARGXB) Cyclically Adjusted Revenue per Share : €9.48 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is argenx SE Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

argenx SE's adjusted revenue per share for the three months ended in Mar. 2025 was €11.138. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €9.48 for the trailing ten years ended in Mar. 2025.

During the past 12 months, argenx SE's average Cyclically Adjusted Revenue Growth Rate was 79.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-29), argenx SE's current stock price is €512.90. argenx SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €9.48. argenx SE's Cyclically Adjusted PS Ratio of today is 54.10.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of argenx SE was 171.16. The lowest was 53.39. And the median was 84.70.


argenx SE Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for argenx SE's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Cyclically Adjusted Revenue per Share Chart

argenx SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.49 4.45 7.97

argenx SE Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.18 5.91 6.87 7.97 9.48

Competitive Comparison of argenx SE's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, argenx SE's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where argenx SE's Cyclically Adjusted PS Ratio falls into.


;
;

argenx SE Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, argenx SE's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=11.138/133.3300*133.3300
=11.138

Current CPI (Mar. 2025) = 133.3300.

argenx SE Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.092 99.050 0.124
201503 0.077 99.750 0.103
201506 0.098 100.230 0.130
201509 0.146 100.500 0.194
201512 0.110 99.730 0.147
201603 0.143 100.310 0.190
201606 0.168 100.260 0.223
201609 0.245 100.570 0.325
201612 0.173 100.710 0.229
201703 0.256 101.440 0.336
201706 0.615 101.370 0.809
201709 0.240 102.030 0.314
201712 0.271 101.970 0.354
201803 0.172 102.470 0.224
201806 0.365 103.100 0.472
201809 0.058 103.950 0.074
201812 0.035 103.970 0.045
201903 0.913 105.370 1.155
201906 0.199 105.840 0.251
201909 0.183 106.700 0.229
201912 0.469 106.800 0.586
202006 0.000 107.510 0.000
202012 0.000 107.850 0.000
202103 2.660 108.870 3.258
202106 4.466 109.670 5.429
202109 0.014 110.790 0.017
202112 0.447 114.010 0.523
202203 0.408 119.460 0.455
202206 1.298 119.050 1.454
202209 2.524 126.890 2.652
202212 2.969 124.940 3.168
202303 3.684 124.720 3.938
202306 4.473 125.830 4.740
202309 5.316 127.160 5.574
202312 6.308 126.450 6.651
202403 6.220 128.580 6.450
202406 7.459 129.910 7.655
202409 7.854 131.610 7.957
202412 10.588 131.630 10.725
202503 11.138 133.330 11.138

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


argenx SE  (CHIX:ARGXb) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

argenx SE's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=512.90/9.48
=54.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of argenx SE was 171.16. The lowest was 53.39. And the median was 84.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


argenx SE Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of argenx SE's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (CHIX:ARGXb) » Definitions » Cyclically Adjusted Revenue per Share
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines